Cell Biology, Tata Translational Cancer Research Centre, Kolkata, India.
Division of Cancer Sciences, University of Manchester, Manchester, UK.
Cancer Med. 2023 Apr;12(8):9293-9302. doi: 10.1002/cam4.5677. Epub 2023 Feb 13.
The north and north-eastern regions of India have among the highest incidence of gallbladder cancer (GBC) in the world. We report the clinicopathological charateristics and outcome of GBC patients in India.
Electronic medical records of patients diagnosed with GBC at Tata Medical Center, Kolkata between 2017 and 2019 were analyzed.
There were 698 cases of confirmed GBC with a median age of 58 (IQR: 50-65) years and female:male ratio of 1.96. At presentation, 91% (496/544) had stage III/IV disease and 30% (189/640) had incidental GBC. The 2-year overall survival (OS) was 100% (95% CI: 100-100); 61% (95% CI: 45-83); 30% (95% CI: 21-43); and 9% (95% CI: 6-13) for stages I-IV, respectively (p = <0.0001). For all patients, the 2-year OS in patients who had a radical cholecystectomy followed by adjuvant therapy (N = 36) was 50% (95% CI: 39-64), compared to 29% (95% CI: 22-38) for those who had a simple cholecystectomy and/or chemotherapy (N = 265) and 9% (95% CI: 6-14) in patients who were palliated (N = 107) (p = <0.0001).
The combined surgical/chemotherapy approach for patients with stage II GBC showed the best outcomes. Early detection of GBC remains problematic with the majority of patients presenting with stage III-IV and who have a median survival of 9.1 months. Our data suggests that the tumor is chemoresponsive and multi-center collaborative clinical trials to identify alternative therapies are urgently required.
印度的北部和东北部地区是全球胆囊癌(GBC)发病率最高的地区之一。我们报告了印度 GBC 患者的临床病理特征和结局。
分析了 2017 年至 2019 年在加尔各答塔塔医疗中心诊断为 GBC 的患者的电子病历。
共有 698 例确诊的 GBC 病例,中位年龄为 58 岁(IQR:50-65),男女比例为 1.96。初诊时,91%(496/544)为 III/IV 期疾病,30%(189/640)为意外 GBC。2 年总生存率(OS)为 100%(95%CI:100-100);61%(95%CI:45-83);30%(95%CI:21-43);9%(95%CI:6-13)分别为 I-IV 期(p<0.0001)。对于所有患者,行根治性胆囊切除术加辅助治疗(N=36)的患者 2 年 OS 为 50%(95%CI:39-64),而单纯行胆囊切除术和/或化疗(N=265)的患者 2 年 OS 为 29%(95%CI:22-38),而行姑息治疗(N=107)的患者 2 年 OS 为 9%(95%CI:6-14)(p<0.0001)。
对于 II 期 GBC 患者,联合手术/化疗方法效果最佳。大多数患者就诊时已处于 III-IV 期,中位生存期为 9.1 个月,这表明早期发现 GBC 仍然存在问题。我们的数据表明肿瘤对化疗有反应,迫切需要多中心协作临床试验来确定替代疗法。